Apixaban 5 and 2.5 Mg Twice-daily Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients: Comparative Effectiveness and Safety Evaluated Using a Propensity-score-matched Approach

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jan 27

PMID 29373602

Citations 12

Authors

Xiaoyan Li

Allison Keshishian

Melissa Hamilton

Ruslan Horblyuk

Kiran Gupta

Xuemei Luo

Jack Mardekian

Keith Friend

Anagha Nadkarni

Xianying Pan

Gregory Y H Lip

Steve Deitelzweig

Affiliations

Soon will be listed here.

Abstract

Trial Registration: Clinicaltrials.Gov Identifier: NCT03087487.

Citing Articles

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study.

Al Sulaiman K, Badreldin H, Korayem G, Alenazi A, Alsuwayyid F, Alrashidi A Thromb J. 2022; 20(1):25.

PMID: 35501916 PMC: 9063081. DOI: 10.1186/s12959-022-00379-x.

Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.

Badescu M, Badulescu O, Butnariu L, Floria M, Ciocoiu M, Costache I J Pers Med. 2022; 12(4).

PMID: 35455634 PMC: 9029474. DOI: 10.3390/jpm12040519.

Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.

Perreault S, Dragomir A, Cote R, Lenglet A, de Denus S, Dorais M Front Pharmacol. 2022; 12:812018.

PMID: 35095525 PMC: 8795908. DOI: 10.3389/fphar.2021.812018.

Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation.

Gozzo L, Di Lenarda A, Mammarella F, Olimpieri P, Cirilli A, Cuomo M Sci Rep. 2021; 11(1):20689.

PMID: 34667256 PMC: 8526656. DOI: 10.1038/s41598-021-99818-4.

Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: A retrospective, observational study.

Chen I, Chang W, Hsu P, Yeh Y, Zheng S, Huang Y Medicine (Baltimore). 2021; 100(23):e26272.

PMID: 34115024 PMC: 8202542. DOI: 10.1097/MD.0000000000026272.

References

Lamberts M, Staerk L, Olesen J, Fosbol E, Hansen M, Harboe L . Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc. 2017; 6(2). PMC: 5523754. DOI: 10.1161/JAHA.116.004517. View

Halvorsen S, Ghanima W, Tvete I, Hoxmark C, Falck P, Solli O . A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2016; 3(1):28-36. PMC: 5216196. DOI: 10.1093/ehjcvp/pvw031. View

Freedman B, Lip G . "Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost. 2016; 116(4):587-9. DOI: 10.1160/TH16-08-0658. View

Gomez-Outes A, Suarez-Gea M, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernandez C . Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol. 2011; 9(2):83-104. DOI: 10.2174/1570163811209020083. View

Alexander J, Andersson U, Lopes R, Hijazi Z, Hohnloser S, Ezekowitz J . Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016; 1(6):673-81. DOI: 10.1001/jamacardio.2016.1829. View

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):e199-267. PMC: 4676081. DOI: 10.1161/CIR.0000000000000041. View

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K . Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017; 117(6):1072-1082. PMC: 6291856. DOI: 10.1160/TH17-01-0068. View

Broder M, Neary M, Chang E, Cherepanov D, Katznelson L . Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2013; 17(4):333-41. DOI: 10.1007/s11102-013-0506-0. View

10.

Forslund T, Wettermark B, Andersen M, Hjemdahl P . Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2017; 20(3):420-428. DOI: 10.1093/europace/euw416. View

11.

Wallentin L, Lopes R, Hanna M, Thomas L, Hellkamp A, Nepal S . Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013; 127(22):2166-76. DOI: 10.1161/CIRCULATIONAHA.112.142158. View

12.

Lip G, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R . Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016; 116(5):975-986. DOI: 10.1160/TH16-05-0403. View

13.

Jensen P, Johnson K, Floyd J, Heckbert S, Carnahan R, Dublin S . A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:141-7. PMC: 3674852. DOI: 10.1002/pds.2317. View

14.

Lip G, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C . Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract. 2016; 70(9):752-63. PMC: 5129572. DOI: 10.1111/ijcp.12863. View

15.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

16.

Staerk L, Fosbol E, Lip G, Lamberts M, Bonde A, Torp-Pedersen C . Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2016; 38(12):907-915. DOI: 10.1093/eurheartj/ehw496. View

17.

Weycker D, Li X, Barron R, Wu H, Morrow P, Xu H . Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. J Natl Compr Canc Netw. 2015; 13(8):979-86. DOI: 10.6004/jnccn.2015.0118. View

18.

Larsen T, Skjoth F, Nielsen P, Kjaeldgaard J, Lip G . Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016; 353:i3189. PMC: 4910696. DOI: 10.1136/bmj.i3189. View

19.

Austin P . The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2013; 33(7):1242-58. PMC: 4285179. DOI: 10.1002/sim.5984. View

20.

Mekaj Y, Mekaj A, Duci S, Miftari E . New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015; 11:967-77. PMC: 4485791. DOI: 10.2147/TCRM.S84210. View